May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Cancer's Toll Beyond the Disease: Medical Costs and Productivity
Rivaroxaban Safe and Effective in Cancer Patients With Thrombosis
OB-GYN Groups Say Insurers' Genetic Testing Rules Limit Access to Care